BRAF and neoplasm: Ganetespib inhibited tumor growth in mice xenografts [122], significantly potentiated the tumor growth inhibitory effect of BRAF and MEK inhibitors, and overcame mechanisms of primary and acquired resistance of melanoma cells to BRAF inhibitors [121, 122].